Streetbeat News

ARAV

Aravive Inc

https://aravive.com/

CEO

Gail McIntyre

Employees

Industry

Pharmaceutical Preparation Manufacturing

versartis, inc. (nasdaq: vsar) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. the company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. versartis’ mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. learn more at www.versartis.com.

Open

0.04

Mkt cap

2.9M

Volume

High

0.05

P/E Ratio

-0.05

52-wk high

2.46

Low

0.04

Div yield

N/A

52-wk low

0.04

M.D.C. Holdings, Inc. (NYSE:MDC) shares rose by approximately 17% in pre-market trading after announcing an acquisition agreement with Sekisui House, Ltd., where a subsidiary of Sekisui House will acquire MDC for $4.9 billion in cash. Other stocks experienced significant movement in pre-market trading, with notable gainers including Lytus Technologies Holdings PTV. Ltd. (LYT) and Marpai, Inc. (MRAI), and losers such as Aravive, Inc. (ARAV) and Nuvve Holding Corp. (NVVE).

Portfolio Pulse from Avi Kapoor

January 18, 2024 | 12:52 pm

Trading for ARAV was halted and then resumed with updated quotation status at 4:35:00 PM ET. The halt was likely due to news pending or an event that needed to be disseminated to the public.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 9:35 pm

Aravive, Inc. has announced its intention to delist from the Nasdaq stock exchange. This decision will result in the company's shares no longer being traded on a major market, which could affect liquidity and visibility for investors. The delisting process typically involves a formal notification to the exchange, followed by the removal of the stock from the exchange's listings. Shareholders may face challenges with trading and the stock may trade on a less regulated over-the-counter (OTC) market post-delisting.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 9:10 pm

Trading on the stock ARAV has been halted at 4:01:00 p.m. ET due to pending news. The halt is in place to manage market orderliness and ensure fair information dissemination pending a significant announcement.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 9:01 pm

Aravive, Inc. has filed a U.S. patent application for methods of treating metastatic cancers using AXL decoy receptors. The patent application number is 20240009271. This could potentially enhance Aravive's intellectual property portfolio and strengthen its position in cancer treatment research.

Portfolio Pulse from Charles Gross

January 11, 2024 | 3:39 pm

In Friday's after-market session, several healthcare stocks experienced significant movements. Comera Life Sciences (CMRA), SenesTech (SNES), Aravive (ARAV), China SXT Pharmaceuticals (SXTC), Co-Diagnostics (CODX), and Oncternal Therapeutics (ONCT) saw gains following their Q3 earnings reports. Conversely, XTL Biopharmaceuticals (XTLB), NeuroMetrix (NURO), TRACON Pharma (TCON), Jaguar Health (JAGX), Intelligent Bio Solutions (INBS), and Sunshine Biopharma (SBFM) experienced declines. The movements were attributed to recent earnings reports and trading volumes.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 9:31 pm

During Wednesday's pre-market session, several health care stocks experienced significant movement. Reshape Lifesciences, BioXcel Therapeutics, TScan Therapeutics, Cue Health, Sonendo, and Aravive saw their stocks rise, with Reshape Lifesciences leading the gainers with a 50.9% increase. On the other hand, Sonnet BioTherapeutics, Tharimmune, Alphatec Holdings, Titan Pharma, Motus GI Hldgs, and Health Catalyst saw their stocks fall, with Sonnet BioTherapeutics experiencing the largest decrease of 34.8%.

Portfolio Pulse from Benzinga Insights

October 25, 2023 | 1:06 pm

The article lists the stocks that gained and lost the most in Friday's mid-day session. Among the gainers were XORTX Therapeutics, Lipella Pharmaceuticals, and Catalyst Biosciences, while the losers included WEBUY GLOBAL, SolarEdge Technologies, and Processa Pharmaceuticals. Factors influencing these movements include FDA clearances, strategic appointments, acquisitions, and financial results.

Portfolio Pulse from Lisa Levin

October 20, 2023 | 5:45 pm

Several healthcare stocks experienced significant price movements during Friday's intraday session. Notable gainers included Aravive, Lipella Pharmaceuticals, Sagimet Biosciences, Catalyst Biosciences, Redhill Biopharma, and Eiger BioPharmaceuticals. On the other hand, Processa Pharma, Atreca, RVL Pharmaceuticals, Adial Pharmaceuticals, Renovaro Biosciences, and Outlook Therapeutics saw their stock prices decline.

Portfolio Pulse from Benzinga Insights

October 20, 2023 | 5:31 pm

During Friday's pre-market session, several health care stocks experienced significant movement. Lipella Pharmaceuticals, Aravive, American Well, Akso Health Group, Comera Life Sciences, and 180 Life Sciences saw increases in their stock prices, while Processa Pharma, Arcutis Biotherapeutics, SeaStar Medical Holding, Biocept, Atreca, and Meihua Intl Medical Techs experienced decreases.

Portfolio Pulse from Benzinga Insights

October 20, 2023 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.